The approach with sargramostim is unique in that this agent is a growth factor that stimulates many different white blood cells instead of inhibiting them and demonstrates some significant clinical benefits in patients with Crohn's disease, said Dr. Stephen Hanauer, a professor of medicine and clinical pharmacology and chief of gastroenterology at the University of Chicago.